当前位置： SCI文献检索 > Multiple Sclerosis and Related Disorders期刊下所有文献 > Predicting falls and injuries in people with multiple sclerosis using machine learning algorithms.

Predicting falls and injuries in people with multiple sclerosis using machine learning algorithms.

Abstract：

:Falls in people with Multiple Sclerosis (PwMS) is a serious issue. It can lead to a lot of problems including sustaining injuries, losing consciousness and hospitalization. Having a model that can predict the probability of these falls and the factors correlated with them and can help caregivers and family members to have a clearer understanding of the risks of falling and proactively minimizing them. We used historical data and machine learning algorithms to predict three outcomes: falling, sustaining injuries and injury types caused by falling in PwMS. The training dataset for this study includes 606 examples of monthly readings. The predictive attributes are the following: Expanded Disability Status Scale (EDSS), years passed since the diagnosis of MS, age of participants in the beginning of the experiment, participants' gender, type of MS and season (or month). Two types of algorithms, decision tree and gradient boosted trees (GBT) algorithm, were used to train six models to answer these three outcomes. After the models were trained their accuracy was evaluated using cross-validation. The models had a high accuracy with some exceeding 90%. We did not limit model evaluation to one-number assessments and studied the confusion matrices of the models as well. The GBT had a higher class recall and smaller number of underestimations, which make it a more reliable model. The methodology proposed in this study and its findings can help in developing better decision-support tools to assist PwMS.

journal_name

Mult Scler Relat Disord

journal_title

Multiple sclerosis and related disorders

authors

Piryonesi SM,Rostampour S,Piryonesi SA

doi

10.1016/j.msard.2021.102740

subject

Has Abstract

pub_date

2021-01-07 00:00:00

pages

102740

eissn

2211-0348

issn

2211-0356

pii

S2211-0348(21)00006-7

journal_volume

49

pub_type

杂志文章

相关文献

Multiple Sclerosis and Related Disorders文献大全
  • Evolution of multiple sclerosis prevalence and phenotype in Latin America.

    abstract：BACKGROUND:Literature regarding MS epidemiology and phenotype is scarce but has increased markedly over the past years. The objective of the present work is to assess the evolution of the prevalence and phenotype of MS in Latin America during recent years. METHODS:Review of literature. RESULTS:MS prevalence levels ar...

    journal_title：Multiple sclerosis and related disorders

    pub_type： 杂志文章,评审

    doi：10.1016/j.msard.2018.03.014

    authors： Negrotto L,Correale J

    更新日期：2018-05-01 00:00:00

  • Positive association of herpes simplex virus-IgG with multiple sclerosis: A systematic review and meta-analysis.

    abstract：BACKGROUND:Multiple sclerosis (MS) is the most common chronic inflammatory demyelinating disease of the central nervous system (CNS), and whether herpes simplex virus (HSV) infection is associated with the development of MS remains controversial. We aimed to investigate potential associations between MS or clinically i...

    journal_title：Multiple sclerosis and related disorders

    pub_type： 杂志文章

    doi：10.1016/j.msard.2020.102633

    authors： Xu L,Zhang LJ,Yang L,Yang CS,Yi M,Zhang SN,Wang N,Huang CN,Liu MQ

    更新日期：2020-11-19 00:00:00

  • Highly sensitive quantification of optic neuritis intrathecal biomarker CXCL13.

    abstract：BACKGROUND:Elevation of CXCL13, a key regulator of B-cell recruitment in cerebrospinal fluid (CSF) is implicated in multiple sclerosis (MS). OBJECTIVE:to evaluate if measurement of CXCL13 using a highly sensitive assay is of value in acute optic neuritis (ON) patients for the prediction of later MS. METHOD:CXCL13 was...

    journal_title：Multiple sclerosis and related disorders

    pub_type： 杂志文章

    doi：10.1016/j.msard.2020.102281

    authors： Olesen MN,Nilsson AC,Pihl-Jensen G,Soelberg KK,Olsen DA,Brandslund I,Lillevang ST,Madsen JS,Frederiksen JL,Asgari N

    更新日期：2020-09-01 00:00:00

  • Favorable outcome of interferon-beta associated thrombotic microangiopathy following treatment with corticosteroids, plasma exchange and rituximab: A case report.

    abstract：:Thrombotic microangiopathy (TMA) is a rare but increasingly recognized complication of interferon-beta therapy, which can be associated with serious sequelae. We report on a 53-year-old woman with a longstanding history of relapsing-remitting multiple sclerosis, who developed TMA after 15 years of high-dose treatment ...

    journal_title：Multiple sclerosis and related disorders

    pub_type： 杂志文章

    doi：10.1016/j.msard.2016.09.002

    authors： Gerischer LM,Siebert E,Janke O,Jungehuelsing GJ,Ruprecht K

    更新日期：2016-11-01 00:00:00

  • Multiple intracranial lesions with lung adenocarcinoma: A rare case of MOG-IgG-associated encephalomyelitis.

    abstract：BACKGROUND:Myelin oligodendrocyte glycoprotein (MOG) is an important marker on the surface of oligodendrocytes and is associated with many demyelinating diseases. Recently, MOG-IgG-associated encephalomyelitis (MOG-EM) has been proposed as a disease entity with a preliminary diagnosis standard. Some patients with lung ...

    journal_title：Multiple sclerosis and related disorders

    pub_type：

    doi：10.1016/j.msard.2020.102064

    authors： Li K,Zhan Y,Shen X

    更新日期：2020-07-01 00:00:00

  • Evaluating the efficacy and safety of ZytuxTM (Rituximab, AryoGen pharmed) in Iranian multiple sclerosis patients: An observational study.

    abstract：BACKGROUND:Anti-CD20 monoclonal antibodies such as ocrelizumab, rituximab, and ofatumumab target B-cell lineage. Clinical trials have demonstrated their effect on reducing both magnetic resonance imaging (MRI) active lesion burden as well as clinical activity. Zytux™ (Rituximab, AryoGen Pharmed) used in the present stu...

    journal_title：Multiple sclerosis and related disorders

    pub_type： 杂志文章

    doi：10.1016/j.msard.2019.101419

    authors： Naser Moghadasi A,Darki A,Masoumi P,Hashemi SN,Ghadiri F

    更新日期：2019-11-01 00:00:00

  • Prevalence of fatigue and its association with clinical features in progressive and non-progressive forms of Multiple Sclerosis.

    abstract：BACKGROUND:Fatigue is a complex and disabling symptom of Multiple Sclerosis (MS); however, there is conflicting evidence of the relationship between fatigue and clinical features of MS. Furthermore, few studies have considered these relationships specifically in a progressive MS population. AIMS:(1) estimate the preva...

    journal_title：Multiple sclerosis and related disorders

    pub_type： 杂志文章

    doi：10.1016/j.msard.2019.01.011

    authors： Rooney S,Wood L,Moffat F,Paul L

    更新日期：2019-02-01 00:00:00

  • Multimodal neurophysiological evaluation of primary progressive multiple sclerosis - An increasingly valid biomarker, with limits.

    abstract：BACKGROUND:The promising utility of multi-modality evoked potential batteries to objectively measure multi-tract dysfunction has been evaluated by several groups using different methods. OBJECTIVE:To independently evaluate the use of multi-modality evoked potential batteries as surrogate biomarkers for both physical a...

    journal_title：Multiple sclerosis and related disorders

    pub_type： 杂志文章

    doi：10.1016/j.msard.2015.07.009

    authors： Canham LJ,Kane N,Oware A,Walsh P,Blake K,Inglis K,Homewood J,Witherick J,Faulkner H,White P,Lewis A,Furse-Roberts C,Cottrell DA

    更新日期：2015-11-01 00:00:00

  • Positive neurologic phenomena with initiation of dalfampridine for multiple sclerosis.

    abstract：OBJECTIVE:Review cases of positive neurologic phenomena initiated or worsened with dalfampridine in patients with multiple sclerosis. BACKGROUND:Oral, extended release dalfampridine (4-aminopyridine or 4-AP) is a potassium-channel blocker approved for the treatment of gait impairment in multiple sclerosis (MS). The en...

    journal_title：Multiple sclerosis and related disorders

    pub_type： 杂志文章

    doi：10.1016/j.msard.2013.05.003

    authors： Thaera GM,Wingerchuk DM,Carter JL

    更新日期：2014-01-01 00:00:00

  • A fine balance: Immunosuppression and immunotherapy in a patient with multiple sclerosis and COVID-19.

    abstract：BACKGROUND:Treatment decisions in patients with multiple sclerosis (MS) during the coronavirus disease 2019 (COVID-19) pandemic are challenging. It is not known whether and how various disease modifying therapies, especially immunosuppressive drugs, affect COVID-19 risk and disease course. METHODS:Case report RESULTS:...

    journal_title：Multiple sclerosis and related disorders

    pub_type：

    doi：10.1016/j.msard.2020.102182

    authors： Valencia-Sanchez C,Wingerchuk DM

    更新日期：2020-07-01 00:00:00

  • Cognitive and physical fatigue are associated with distinct problems in daily functioning, role fulfilment, and quality of life in multiple sclerosis.

    abstract：OBJECTIVE:To examine whether cognitive and physical fatigue are differentially associated with problems in self-care, mobility, relationships, participation, psychological well-being, and quality of life in people with multiple sclerosis. METHODS:A cross-sectional study involving seventy-four community-dwelling people...

    journal_title：Multiple sclerosis and related disorders

    pub_type： 杂志文章

    doi：10.1016/j.msard.2019.03.024

    authors： Gullo HL,Fleming J,Bennett S,Shum DHK

    更新日期：2019-06-01 00:00:00

  • An extremely aggressive case of Marburg's disease treated with high dose cyclophosphamide. A case report.

    abstract：BACKGROUND:The acute, fulminant type of Multiple Sclerosis (MS), known as Marburg Disease, has been shown to have poor response to conventional acute treatments typically used for demyelinating diseases. METHODS:We report a 20 y/o postpartum female who was consulted to the Neurology service given findings of subacute ...

    journal_title：Multiple sclerosis and related disorders

    pub_type： 杂志文章

    doi：10.1016/j.msard.2019.03.014

    authors： Avila-Ornelas J,Labat E,Alfonso G,Serrano C,Fiorito F

    更新日期：2019-06-01 00:00:00

  • The epidemiology of multiple sclerosis in the Scottish Highlands: Prevalence, incidence and time to confirmed diagnosis and treatment initiation.

    abstract：INTRODUCTION:Although multiple sclerosis (MS) is frequent in the northern hemisphere, there have not been recent epidemiological studies in the Scottish Highlands about MS. OBJECTIVES:To get updated data regarding MS prevalence, incidence and mortality in the Highlands. Time between symptom onset and MS diagnosis was ...

    journal_title：Multiple sclerosis and related disorders

    pub_type： 杂志文章

    doi：10.1016/j.msard.2020.102657

    authors： Carod-Artal FJ

    更新日期：2020-11-28 00:00:00

  • Targeting macrophages by an aza-anthrapyrazole to ameliorate experimental autoimmune encephalomyelitis.

    abstract：BACKGROUND:Multiple sclerosis (MS) is an immune-mediated neurodegenerative disease in the central nerve system, in which both innate and adaptive immune cells are involved. BBR3378, an aza-anthrapyrazole prevents experimental autoimmune encephalomyelitis (EAE), an inflammatory condition similar to MS, by antagonizing T...

    journal_title：Multiple sclerosis and related disorders

    pub_type： 杂志文章

    doi：10.1016/j.msard.2020.102190

    authors： Lin B,Launder D,Bailey DY,Assifuah FK,Miller OA,Conti HR,Du J,Koffman BM

    更新日期：2020-08-01 00:00:00

  • Neuromyelitis optica spectrum disorders in Algeria: A preliminary study in the region of Tizi Ouzou.

    abstract：BACKGROUND:Neuromyelitis optica (NMO) is a disabling inflammatory condition that targets astrocytes in the optic nerves and spinal cord. Recent advances led to the individualization of a set of conditions now referred as NMO spectrum disorder (NMOSD). OBJECTIVE:To describe the prevalence and characteristics of NMO SD ...

    journal_title：Multiple sclerosis and related disorders

    pub_type： 杂志文章

    doi：10.1016/j.msard.2015.12.005

    authors： Daoudi S,Bouzar M

    更新日期：2016-03-01 00:00:00

  • Tonsillectomy in multiple sclerosis patients: Retrospective, case-controlled, exploratory study.

    abstract：BACKGROUND:Previous studies have shown an effect of tonsillectomy and greater risk for future autoimmune diseases. Currently there are only few outdated analyses of tonsillectomy and multiple sclerosis (MS) risk. OBJECTIVE:To investigate the prevalence of tonsillectomy in MS patients and healthy controls (HCs). METHO...

    journal_title：Multiple sclerosis and related disorders

    pub_type： 杂志文章

    doi：10.1016/j.msard.2020.102131

    authors： Jakimovski D,Ahmed MK,Vaughn CB,Zivadinov R,Weinstock-Guttman B

    更新日期：2020-07-01 00:00:00

  • Natalizumab is effective in controlling the inflammatory rebound after its discontinuation and failure of an alternative treatment.

    abstract：:Progressive multifocal leukoencephalopathy (PML) is the most feared complication when natalizumab (NAT) is used in the treatment of relapsing multiple sclerosis (MS). JC virus serologic status is a currently established risk factor for PML. When seroconversion occurs, NAT discontinuation should be based on a solid rat...

    journal_title：Multiple sclerosis and related disorders

    pub_type： 杂志文章

    doi：10.1016/j.msard.2015.04.005

    authors： Barroso B,Miquel M,Marasescu R,Demasles S,Krim E,Bonnan M

    更新日期：2015-07-01 00:00:00

  • Coexistent MOG, NMDAR, CASPR2 antibody positivity: Triumph over the triumvirate.

    abstract：:Myelin oligodendrocyte glycoprotein (MOG) antibody (MOG -Ab) positive cases can have a focal encephalitis like presentation. Many reports of anti N-methyl-D-aspartate receptor (NMDAR) encephalitis have documented simultaneous coexistence of MOG-Ab which is explained by the coexpression of NMDA receptors and MOG on oli...

    journal_title：Multiple sclerosis and related disorders

    pub_type： 信件

    doi：10.1016/j.msard.2020.102468

    authors： Cherian A,Divya KP,Shetty SC,Kannoth S,Thomas B

    更新日期：2020-11-01 00:00:00

  • Alemtuzumab as rescue therapy in case of multiple sclerosis rebound following Natalizumab break: Clinical case and literature review.

    abstract：INTRODUCTION:Natalizumab break exposes multiple sclerosis (MS) patients to a high risk of disease reactivation or rebound, whose prevention and treatment constitute a clinical challenge. CASE PRESENTATION:We describe a dramatic case of MS rebound, characterized by the development of severe neurological and psychiatric...

    journal_title：Multiple sclerosis and related disorders

    pub_type： 杂志文章,评审

    doi：10.1016/j.msard.2019.03.002

    authors： Federle L,Puthenparampil M,Stenta G,Paolo G,Francesco P

    更新日期：2019-05-01 00:00:00

  • Aphasic status epilepticus preceding tumefactive left hemisphere lesion in anti-MOG antibody associated disease.

    abstract：INTRODUCTION:Anti-myelin oligodendrocyte glycoprotein (MOG) antibodies have recently been associated with epilepsy with FLAIR hyperintense cortical lesions on MRI. Association between anti-MOG antibodies and epilepsy without detectable structural brain lesion on MRI is unknown. CASE REPORT:A 48-year-old right-handed m...

    journal_title：Multiple sclerosis and related disorders

    pub_type： 杂志文章

    doi：10.1016/j.msard.2018.10.012

    authors： Katsuse K,Kurihara M,Sugiyama Y,Kodama S,Takahashi M,Momose T,Yumoto M,Kaneko K,Takahashi T,Kubota A,Hayashi T,Toda T

    更新日期：2019-01-01 00:00:00

  • Clinical characteristics and use of disease modifying therapy in the nationwide Danish cohort of paediatric onset multiple sclerosis.

    abstract：BACKGROUND:Several disease-modifying therapies (DMT) are being used in paediatric patients with multiple sclerosis (MS) despite the limited number of randomised controlled clinical trials leading to approved indication in children. OBJECTIVES:The aim of this study was to describe clinical characteristics of the Danish...

    journal_title：Multiple sclerosis and related disorders

    pub_type： 杂志文章

    doi：10.1016/j.msard.2019.101431

    authors： Erdal JL,Kopp TI,Blinkenberg M,Petersen T,Sørensen PS,Magyari M

    更新日期：2020-01-01 00:00:00

  • Functional recovery in multiple sclerosis patients undergoing rehabilitation programs is associated with plasma levels of hemostasis inhibitors.

    abstract：BACKGROUND:Increasing evidence for contribution of hemostasis components in multiple sclerosis (MS) has been reported. Hemostasis protein inhibitors display key regulatory roles, extending to regulation of innate immune response and inflammation, and promotion of blood-brain barrier integrity. Whereas the effects on he...

    journal_title：Multiple sclerosis and related disorders

    pub_type： 杂志文章

    doi：10.1016/j.msard.2020.102319

    authors： Ziliotto N,Lamberti N,Manfredini F,Straudi S,Baroni M,Tisato V,Carantoni M,Secchiero P,Basaglia N,Marchetti G,Bernardi F

    更新日期：2020-09-01 00:00:00

  • Brief international cognitive assessment for multiple sclerosis (BICAMS): A danish validation study of sensitivity in early stages of MS.

    abstract：BACKGROUND:Cognitive impairment is highly prevalent in multiple sclerosis (MS). Due to the lack of specialized neuropsychological resources in many MS clinics, a brief cognitive monitoring tool that can be administered by other MS clinic staff is needed. BICAMS (Brief International Cognitive As-sessment for Multiple Sc...

    journal_title：Multiple sclerosis and related disorders

    pub_type： 杂志文章

    doi：10.1016/j.msard.2019.101458

    authors： Marstrand L,Østerberg O,Walsted T,Skov AC,Schreiber KI,Sellebjerg F

    更新日期：2020-01-01 00:00:00

  • Rituximab-induced serum sickness in multiple sclerosis patients.

    abstract：:Rituximab is a chimeric anti-CD20 monoclonal antibody that is an effective therapy for multiple sclerosis. Rituximab has been associated with the development of serum sickness (type III hypersensitivity) characterized by arthralgia, fever, and rash during the treatment of other conditions, such as rheumatoid arthritis...

    journal_title：Multiple sclerosis and related disorders

    pub_type： 杂志文章

    doi：10.1016/j.msard.2019.101402

    authors： Wolf AB,Ryerson LZ,Pandey K,McGettigan BM,Vollmer T,Corboy JR,Alvarez E

    更新日期：2019-11-01 00:00:00

  • Real-world incidence of fingolimod-associated macular oedema.

    abstract：BACKGROUND:Fingolimod (Gilenya, Novartis, Basel Switzerland) 0.5 mg orally once-daily is widely used for relapsing-remitting multiple sclerosis. Patients are usually screened four months after starting fingolimod for fingolimod-associated macular oedema (FAME). Large registration trials with stringent eligibility crite...

    journal_title：Multiple sclerosis and related disorders

    pub_type： 杂志文章

    doi：10.1016/j.msard.2020.102125

    authors： Goh LY,Kirthi V,Silber E,Harvey JP,Jackson TL

    更新日期：2020-07-01 00:00:00

  • Alemtuzumab outcomes by age: Post hoc analysis from the randomized CARE-MS studies over 8 years.

    abstract：BACKGROUND:Alemtuzumab significantly improved clinical and MRI outcomes vs. subcutaneous interferon beta-1a (SC IFNB-1a) in the CARE-MS trials (NCT00530348, NCT00548405), with sustained efficacy in 2 consecutive extensions (NCT00930553, NCT02255656 [TOPAZ]). METHODS:Post hoc analysis of 8-year alemtuzumab efficacy and...

    journal_title：Multiple sclerosis and related disorders

    pub_type： 杂志文章

    doi：10.1016/j.msard.2020.102717

    authors： Bass AD,Arroyo R,Boster AL,Boyko AN,Eichau S,Ionete C,Limmroth V,Navas C,Pelletier D,Pozzilli C,Ravenscroft J,Sousa L,Tintoré M,Uitdehaag BMJ,Baker DP,Daizadeh N,Choudhry Z,Rog D,CARE-MS I, CARE-MS II, CAMMS03409, and

    更新日期：2020-12-24 00:00:00

  • Racial differences in retinal neurodegeneration as a surrogate marker for cortical atrophy in multiple sclerosis.

    abstract：BACKGROUND:Multiple sclerosis (MS) has both an inflammatory and a neurodegenerative component, with gray matter (GM) atrophy being an important contributor to disability. Optical coherence tomography (OCT) may serve as a prognostic tool for neuroaxonal health by measuring ganglion cell inner plexiform layer (GCIPL) thi...

    journal_title：Multiple sclerosis and related disorders

    pub_type： 杂志文章

    doi：10.1016/j.msard.2019.04.001

    authors： Lichtman-Mikol S,Razmjou S,Yarraguntla K,Bao F,Santiago-Martinez C,Seraji-Bozorgzad N,Bernitsas E

    更新日期：2019-06-01 00:00:00

  • End of dose interval symptoms in patients treated with natalizumab: A role for serum cytokines?

    abstract：BACKGROUND:Many natalizumab treated patients experience end of dose interval (EDI) symptoms towards the end of the administration cycle. Natalizumab has previously shown to influence cytokine profiles in relapsing remitting MS patients. We hypothesize that EDI symptoms might be explained by variability in serum cytokin...

    journal_title：Multiple sclerosis and related disorders

    pub_type： 杂志文章

    doi：10.1016/j.msard.2020.102020

    authors： Cathérine D,Annelien P,Anne S,Luc A,Liesbeth VH,Gerlo S,Guy L

    更新日期：2020-06-01 00:00:00

  • Determinants of quality of life in relapsing-remitting and progressive multiple sclerosis.

    abstract：BACKGROUND:Numerous factors can affect multiple sclerosis (MS) patients' quality of life (QoL). We investigated how physical impairment, upper extremity function, cognitive impairment, cognitive reserve, symptoms of psychological distress, depression, fatigue as well as age and disease duration contribute to patient-re...

    journal_title：Multiple sclerosis and related disorders

    pub_type： 杂志文章

    doi：10.1016/j.msard.2019.01.049

    authors： Yalachkov Y,Soydaş D,Bergmann J,Frisch S,Behrens M,Foerch C,Gehrig J

    更新日期：2019-05-01 00:00:00

  • Quantitative visual tests after poorly recovered optic neuritis due to multiple sclerosis.

    abstract：BACKGROUND:Visual dysfunction in MS can be quantified using a variety of tests. Many vision tests have not been formally evaluated among MS patients with existing visual dysfunction. OBJECTIVE:Evaluate several versions of visual acuity and contrast sensitivity tests, measures of central and peripheral vision, retina s...

    journal_title：Multiple sclerosis and related disorders

    pub_type： 杂志文章

    doi：10.1016/j.msard.2016.10.009

    authors： Longbrake EE,Lancia S,Tutlam N,Trinkaus K,Naismith RT

    更新日期：2016-11-01 00:00:00